King Pharmaceuticals, Inc. v. Purdue Pharma L.P.

OPINION AND ORDER

JAMES P. JONES, Chief Judge.

In this patent infringement action, following a so-called Markman proceeding, I construe as a matter of law the disputed claims of the subject patents.

I

The patents at the center of this dispute, U.S. Patent No. 6,696,088 (“the '088 patent”) and its continuation, U.S. Patent No. 7,658,939 (“the '939 patent”), are both entitled “Tamper-Resistant Oral Opioid Agonist Formulations” and owned by the defendant, Purdue Pharma L.P. (“Purdue”). In their Supplemental Complaint, the plaintiffs, King Pharmaceuticals, Inc. and its wholly-owned subsidiary,…